1. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Issue 10226 (7th March 2020) Authors: Spring, Laura M; Wander, Seth A; Andre, Fabrice; Moy, Beverly; Turner, Nicholas C; Bardia, Aditya Journal: Lancet Issue: Volume 395:Issue 10226(2020) Page Start: 817 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population. (December 2021) Authors: Beyerlin, Kassidy; Jimenez, Rachel; Zangardi, Mark; Fell, Geoffrey G; Edmonds, Christine; Johnson, Andrew; Bossuyt, Veerle; Specht, Michelle; Mulvey, Therese M; Moy, Beverly; Ellisen, Leif W; Isakoff, Steven J; Bardia, Aditya; Spring, Laura M Journal: Journal of oncology pharmacy practice Issue: Volume 27:Number 8(2021) Page Start: 1883 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. Issue 6 (June 2019) Authors: Wander, Seth A; Spring, Laura M; Bardia, Aditya Journal: Lancet oncology Issue: Volume 20:Issue 6(2019) Page Start: 746 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies. Issue 2 (2022) Authors: Keenan, Jennifer C; Ryan, Phoebe K; Medford, Arielle J; Spring, Laura M; Bardia, Aditya Journal: Touch reviews in oncology & haematology Issue: Volume 18:Issue 2(2022) Page Start: 98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗